메뉴 건너뛰기




Volumn 17, Issue 1, 2018, Pages

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Author keywords

Diabetes; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor; Stroke

Indexed keywords

EXENDIN 4; LINAGLIPTIN; LIXISENATIDE; SEMAGLUTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

EID: 85042436267     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-018-0674-3     Document Type: Note
Times cited : (15)

References (20)
  • 1
    • 84957878858 scopus 로고    scopus 로고
    • Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    • Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203-16.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.3 , pp. 203-216
    • Nauck, M.1
  • 3
    • 84875438002 scopus 로고    scopus 로고
    • The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride
    • Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, Klein T, Sjoholm A, Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289-96.
    • (2013) Diabetes , vol.62 , Issue.4 , pp. 1289-1296
    • Darsalia, V.1    Ortsater, H.2    Olverling, A.3    Darlof, E.4    Wolbert, P.5    Nystrom, T.6    Klein, T.7    Sjoholm, A.8    Patrone, C.9
  • 4
    • 85042442686 scopus 로고    scopus 로고
    • Glucagon-like receptor 1 agonists and DPP-4 inhibitors: anti-diabetic drugs with anti-stroke potential
    • Darsalia V, Klein T, Nystrom T, Patrone C. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: anti-diabetic drugs with anti-stroke potential. Neuropharmacology. 2017. https://doi.org/10.1016/j.neuropharm.2017.08.022.
    • (2017) Neuropharmacology
    • Darsalia, V.1    Klein, T.2    Nystrom, T.3    Patrone, C.4
  • 5
    • 85029679644 scopus 로고    scopus 로고
    • Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    • Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849-70.
    • (2017) Circulation , vol.136 , Issue.9 , pp. 849-870
    • Nauck, M.A.1    Meier, J.J.2    Cavender, M.A.3    Abd El Aziz, M.4    Drucker, D.J.5
  • 6
    • 85042432121 scopus 로고    scopus 로고
    • Effects of glucose-lowering agents on ischemic stroke
    • Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes. 2017;8(6):270-7.
    • (2017) World J Diabetes , vol.8 , Issue.6 , pp. 270-277
    • Avgerinos, K.1    Tziomalos, K.2
  • 7
    • 84969506808 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
    • Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5:CD012204.
    • (2017) Cochrane Database Syst Rev , vol.5
    • Hemmingsen, B.1    Sonne, D.P.2    Metzendorf, M.I.3    Richter, B.4
  • 11
    • 85029218795 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    • Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):112.
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 112
    • Gantz, I.1    Chen, M.2    Suryawanshi, S.3    Ntabadde, C.4    Shah, S.5    O'Neill, E.A.6    Engel, S.S.7    Kaufman, K.D.8    Lai, E.9
  • 12
    • 85014351364 scopus 로고    scopus 로고
    • Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    • Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16(1):31.
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 31
    • Zhang, Z.1    Chen, X.2    Lu, P.3    Zhang, J.4    Xu, Y.5    He, W.6    Li, M.7    Zhang, S.8    Jia, J.9    Shao, S.10
  • 14
    • 85007489154 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis
    • Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis. Diabetes Metab. 2017;43(1):1-8.
    • (2017) Diabetes Metab , vol.43 , Issue.1 , pp. 1-8
    • Barkas, F.1    Elisaf, M.2    Tsimihodimos, V.3    Milionis, H.4
  • 15
    • 85042450975 scopus 로고    scopus 로고
    • Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
    • Li YR, Tsai SS, Chen DY, Chen ST, Sun JH, Chang HY, Liou MJ, Chen TH. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovasc Diabetol. 2018;17(1):2.
    • (2018) Cardiovasc Diabetol , vol.17 , Issue.1 , pp. 2
    • Li, Y.R.1    Tsai, S.S.2    Chen, D.Y.3    Chen, S.T.4    Sun, J.H.5    Chang, H.Y.6    Liou, M.J.7    Chen, T.H.8
  • 18
    • 85030707291 scopus 로고    scopus 로고
    • Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
    • Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology. 2017. https://doi.org/10.1016/j.neuropharm.2017.09.023.
    • (2017) Neuropharmacology
    • Athauda, D.1    Foltynie, T.2
  • 20
    • 84922274240 scopus 로고    scopus 로고
    • Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register
    • Ullberg T, Zia E, Petersson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. Stroke. 2015;46(2):389-94.
    • (2015) Stroke , vol.46 , Issue.2 , pp. 389-394
    • Ullberg, T.1    Zia, E.2    Petersson, J.3    Norrving, B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.